Efficacy and Safety of IV Diclofenac (DIC075V) for Pain After Abdominal or Pelvic Surgery

NCT ID: NCT00448110

Last Updated: 2009-05-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

331 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2007-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will compare repeated intermittent IV dosing of diclofenac in patients with moderate to severe post-surgical pain from abdominal or pelvic surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective is to evaluate the efficacy and safety of two dosage levels of parenteral diclofenac in providing pain relief as compared to placebo or Ketorolac tromethamine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Postoperative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

intravenous diclofenac dosage level 1

Group Type EXPERIMENTAL

Intravenous Diclofenac (DIC075V)

Intervention Type DRUG

Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels

B

intravenous diclofenac dosage level 2

Group Type EXPERIMENTAL

Intravenous Diclofenac (DIC075V)

Intervention Type DRUG

Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels

C

intravenous ketorolac

Group Type ACTIVE_COMPARATOR

Intravenous Ketorolac

Intervention Type DRUG

Intravenous Ketorolac

D

placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intravenous Diclofenac (DIC075V)

Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels

Intervention Type DRUG

Intravenous Ketorolac

Intravenous Ketorolac

Intervention Type DRUG

placebo

placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Scheduled within two weeks of the screening visit to undergo abdominal or pelvic surgery
* Moderate to severe pain within 6 hours following completion of the required surgery.

Exclusion Criteria

* Surgical procedure involves a subcostal incision.
* Chronic disease or recent cardiovascular events.
* Known allergy or hypersensitivity to the active compounds or any of the excipients used in the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Javelin Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Javelin Pharmaceuticals

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Javelin Pharmaceuticals

Role: STUDY_DIRECTOR

Javelin Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alabama Clinical Therapeutics

Birmingham, Alabama, United States

Site Status

Eliza Coffee Memorial Hospital

Florence, Alabama, United States

Site Status

Drug Research and Analysis Corp.

Montgomery, Alabama, United States

Site Status

Helen Keller Hospital

Sheffield, Alabama, United States

Site Status

Teton Research / Parkview Surgical

Little Rock, Arkansas, United States

Site Status

Glendale Adventist Medical Center

Glendale, California, United States

Site Status

Saddleback Memorial Medical Center

Laguna Hills, California, United States

Site Status

Visions Clinical Research

Boynton Beach, Florida, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

Clinical Research Services

Bismarck, North Dakota, United States

Site Status

Clinical Research Center

Austin, Texas, United States

Site Status

Memorial Hermann Healthcare System - Memorial City Hospital

Houston, Texas, United States

Site Status

Clinical Research Center

San Marcos, Texas, United States

Site Status

Jean Brown Research

Salt Lake City, Utah, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Chelly JE, Lacouture PG, Reyes CRD. Safety of Injectable HPbetaCD-Diclofenac in Older Patients with Acute Moderate-to-Severe Postoperative Pain: A Pooled Analysis of Three Phase III Trials. Drugs Aging. 2018 Mar;35(3):249-259. doi: 10.1007/s40266-018-0529-3.

Reference Type DERIVED
PMID: 29492863 (View on PubMed)

Gan TJ, Daniels SE, Singla N, Hamilton DA, Carr DB. A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesth Analg. 2012 Nov;115(5):1212-20. doi: 10.1213/ANE.0b013e3182691bf9. Epub 2012 Aug 10.

Reference Type DERIVED
PMID: 22886837 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DFC-004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.